Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
439 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peritoneal Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H1 2015', provides an overview of the Peritoneal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Peritoneal Cancer Overview 11 Therapeutics Development 12 Pipeline Products for Peritoneal Cancer - Overview 12 Pipeline Products for Peritoneal Cancer - Comparative Analysis 13 Peritoneal Cancer - Therapeutics under Development by Companies 14 Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 19 Peritoneal Cancer - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Peritoneal Cancer - Products under Development by Companies 23 Peritoneal Cancer - Products under Investigation by Universities/Institutes 28 Peritoneal Cancer - Companies Involved in Therapeutics Development 29 AbbVie Inc. 29 Acceleron Pharma, Inc. 30 Adaptimmune Limited 31 Advanced Accelerator Applications SA 32 Amgen Inc. 33 Astellas Pharma Inc. 34 Astex Pharmaceuticals, Inc. 35 AstraZeneca PLC 36 Basilea Pharmaceutica AG 37 Bayer AG 38 BioMarin Pharmaceutical Inc. 39 Bionomics Limited 40 Boehringer Ingelheim GmbH 41 Celldex Therapeutics, Inc. 42 Celsion Corporation 43 Cerulean Pharma, Inc. 44 Clovis Oncology, Inc. 45 Corcept Therapeutics Incorporated 46 CritiTech, Inc. 47 CTI BioPharma Corp. 48 Eli Lilly and Company 49 Exelixis, Inc. 50 F. Hoffmann-La Roche Ltd. 51 Galena Biopharma, Inc. 52 Genelux Corporation 53 Genentech, Inc. 54 GlaxoSmithKline plc 55 Glycotope GmbH 56 Hemispherx Biopharma, Inc. 57 ImmunoGen, Inc. 58 Immunotope, Inc. 59 Immunovaccine, Inc. 60 Johnson & Johnson 61 Lee's Pharmaceutical Holdings Limited 62 MabVax Therapeutics Holdings, Inc. 63 MedImmune, LLC 64 Merck & Co., Inc. 65 Merrimack Pharmaceuticals, Inc. 66 NeoStem, Inc. 67 Novartis AG 68 Neovii Biotech GmbH 69 Oasmia Pharmaceutical AB 70 OBI Pharma, Inc. 71 Oncolytics Biotech Inc. 72 OncoMed Pharmaceuticals, Inc. 73 Onxeo SA 74 Oxford BioMedica plc 75 OXiGENE, Inc. 76 Pharma Mar, S.A. 77 Pharmacyclics, Inc. 78 PsiOxus Therapeutics, Ltd. 79 Recepta Biopharma S.A. 80 Sanofi Pasteur SA 81 Synta Pharmaceuticals Corp. 82 Takeda Oncology 83 TapImmune Inc. 84 TetraLogic Pharmaceuticals 85 TRACON Pharmaceuticals, Inc. 86 VentiRx Pharmaceuticals, Inc. 87 Peritoneal Cancer - Therapeutics Assessment 88 Assessment by Monotherapy Products 88 Assessment by Target 89 Assessment by Mechanism of Action 94 Assessment by Route of Administration 98 Assessment by Molecule Type 100 Drug Profiles 102 ���Pb-TCMC-Trastuzumab - Drug Profile 102 abexinostat hydrochloride - Drug Profile 104 abiraterone acetate - Drug Profile 106 ABT-767 - Drug Profile 109 alisertib - Drug Profile 110 anetumab ravtansine - Drug Profile 114 AZD-1775 - Drug Profile 116 AZD-2014 - Drug Profile 118 AZD-5363 - Drug Profile 120 BAL-101553 - Drug Profile 122 belinostat - Drug Profile 123 bevacizumab - Drug Profile 126 binimetinib - Drug Profile 131 birinapant - Drug Profile 135 BNC-105P - Drug Profile 138 cabozantinib s-malate - Drug Profile 140 Cancer Stem Cell Therapy - Drug Profile 143 catumaxomab - Drug Profile 144 CDX-1401 - Drug Profile 146 Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 148 Cell Therapy to Target WT1 for Cancer - Drug Profile 150 CRLX-101 - Drug Profile 151 dalantercept - Drug Profile 153 demcizumab - Drug Profile 155 Dendritic Cell Therapy for Cancer - Drug Profile 159 Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile 160 DMUC-4064A - Drug Profile 161 DPX-Survivac - Drug Profile 162 EGEN-001 - Drug Profile 165 elesclomol - Drug Profile 167 enadenotucirev - Drug Profile 169 erismodegib - Drug Profile 171 fosbretabulin tromethamine - Drug Profile 174 GALE-301 - Drug Profile 178 ganetespib - Drug Profile 180 gimatecan - Drug Profile 184 GLONC-1 - Drug Profile 186 guadecitabine - Drug Profile 189 IMGN-853 - Drug Profile 192 IMT-1012 - Drug Profile 193 ipafricept - Drug Profile 194 LCL-161 - Drug Profile 195 lifastuzumab vedotin - Drug Profile 197 linsitinib - Drug Profile 199 LY-2606368 - Drug Profile 201 MesoCART - Drug Profile 202 mifepristone - Drug Profile 203 MK-2206 - Drug Profile 205 Monoclonal Antibody Conjugate to Target B7-H3 for Cancer - Drug Profile 208 motolimod - Drug Profile 209 MV-NIS - Drug Profile 211 nintedanib - Drug Profile 213 NSC-748933 - Drug Profile 217 OBI-822/821 - Drug Profile 218 olaratumab - Drug Profile 220 paclitaxel - Drug Profile 222 paclitaxel - Drug Profile 224 paclitaxel poliglumex - Drug Profile 225 PankoMab-GEX - Drug Profile 229 pazopanib hydrochloride - Drug Profile 230 pelareorep - Drug Profile 235 ralimetinib mesylate - Drug Profile 240 ramucirumab - Drug Profile 241 RebmAb-100 - Drug Profile 246 regorafenib - Drug Profile 248 rintatolimod - Drug Profile 251 rucaparib phosphate - Drug Profile 252 selumetinib sulfate - Drug Profile 255 seribantumab - Drug Profile 258 SG-2000 - Drug Profile 260 sofituzumab vedotin - Drug Profile 262 sorafenib tosylate - Drug Profile 263 talazoparib - Drug Profile 267 Theranean - Drug Profile 269 TPIV-200 - Drug Profile 270 trabectedin - Drug Profile 272 TRC-105 - Drug Profile 275 trebananib - Drug Profile 277 TroVax - Drug Profile 280 Vaccine for Oncology - Drug Profile 283 Vaccine to Target Carcinoembryonic Antigen for Oncology - Drug Profile 284 vCP-2292 - Drug Profile 285 X-82 - Drug Profile 286 Peritoneal Cancer - Recent Pipeline Updates 287 Peritoneal Cancer - Dormant Projects 428 Peritoneal Cancer - Discontinued Products 429 Peritoneal Cancer - Product Development Milestones 430 Featured News & Press Releases 430 Appendix 433 Methodology 433 Coverage 433 Secondary Research 433 Primary Research 433 Expert Panel Validation 433 Contact Us 434 Disclaimer 434
List of Tables Number of Products under Development for Peritoneal Cancer, H1 2015 17 Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2015 18 Number of Products under Development by Companies, H1 2015 20 Number of Products under Development by Companies, H1 2015 (Contd..1) 21 Number of Products under Development by Companies, H1 2015 (Contd..2) 22 Number of Products under Development by Companies, H1 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2015 24 Comparative Analysis by Late Stage Development, H1 2015 25 Comparative Analysis by Clinical Stage Development, H1 2015 26 Comparative Analysis by Early Stage Development, H1 2015 27 Products under Development by Companies, H1 2015 28 Products under Development by Companies, H1 2015 (Contd..1) 29 Products under Development by Companies, H1 2015 (Contd..2) 30 Products under Development by Companies, H1 2015 (Contd..3) 31 Products under Development by Companies, H1 2015 (Contd..4) 32 Products under Investigation by Universities/Institutes, H1 2015 33 Peritoneal Cancer - Pipeline by AbbVie Inc., H1 2015 34 Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 35 Peritoneal Cancer - Pipeline by Adaptimmune Limited, H1 2015 36 Peritoneal Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2015 37 Peritoneal Cancer - Pipeline by Amgen Inc., H1 2015 38 Peritoneal Cancer - Pipeline by Astellas Pharma Inc., H1 2015 39 Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 40 Peritoneal Cancer - Pipeline by AstraZeneca PLC, H1 2015 41 Peritoneal Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2015 42 Peritoneal Cancer - Pipeline by Bayer AG, H1 2015 43 Peritoneal Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 44 Peritoneal Cancer - Pipeline by Bionomics Limited, H1 2015 45 Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46 Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 47 Peritoneal Cancer - Pipeline by Celsion Corporation, H1 2015 48 Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 49 Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 50 Peritoneal Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 51 Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2015 52 Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H1 2015 53 Peritoneal Cancer - Pipeline by Eli Lilly and Company, H1 2015 54 Peritoneal Cancer - Pipeline by Exelixis, Inc., H1 2015 55 Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 56 Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 57 Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2015 58 Peritoneal Cancer - Pipeline by Genentech, Inc., H1 2015 59 Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 60 Peritoneal Cancer - Pipeline by Glycotope GmbH, H1 2015 61 Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2015 62 Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2015 63 Peritoneal Cancer - Pipeline by Immunotope, Inc., H1 2015 64 Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2015 65 Peritoneal Cancer - Pipeline by Johnson & Johnson, H1 2015 66 Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 67 Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 68 Peritoneal Cancer - Pipeline by MedImmune, LLC, H1 2015 69 Peritoneal Cancer - Pipeline by Merck & Co., Inc., H1 2015 70 Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 71 Peritoneal Cancer - Pipeline by NeoStem, Inc., H1 2015 72 Peritoneal Cancer - Pipeline by Novartis AG, H1 2015 73 Peritoneal Cancer - Pipeline by Neovii Biotech GmbH, H1 2015 74 Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 75 Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H1 2015 76 Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 77 Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 78 Peritoneal Cancer - Pipeline by Onxeo SA, H1 2015 79 Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H1 2015 80 Peritoneal Cancer - Pipeline by OXiGENE, Inc., H1 2015 81 Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2015 82 Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 83 Peritoneal Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 84 Peritoneal Cancer - Pipeline by Recepta Biopharma S.A., H1 2015 85 Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 86 Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 87 Peritoneal Cancer - Pipeline by Takeda Oncology, H1 2015 88 Peritoneal Cancer - Pipeline by TapImmune Inc., H1 2015 89 Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 90 Peritoneal Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 91 Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 92 Assessment by Monotherapy Products, H1 2015 93 Number of Products by Stage and Target, H1 2015 95 Number of Products by Stage and Mechanism of Action, H1 2015 100 Number of Products by Stage and Route of Administration, H1 2015 104 Number of Products by Stage and Molecule Type, H1 2015 106 Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 292 Peritoneal Cancer - Dormant Projects, H1 2015 432 Peritoneal Cancer - Discontinued Products, H1 2015 433
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
